Accelerated Pharmaceutical eXploration (APX) is a specialized platform that leverages artificial intelligence (AI) and machine learning (ML) technologies to advance drug discovery and development.
Embedded Files
Integrated computational biology & omics data Identify genetic alterations associated with disease. This information can be used to develop diagnostic tests and to better understand the pathogenesis of diseases, predicting patient outcomes, personalizing treatment.
Generative AI and LLMs (Large Language Models) offer exciting possibilities for predictive analysis in genomic medicine , single-cell spatial multi-omics data analysis.
Cognitive Drug Discovery = knowledge graphs+ LLMs+ GenAI+ GraphRAG
Highlight the integration of cutting-edge AI technologies and methodologies, emphasizing the transformative potential of these tools in the drug discovery
Please scroll over the pages here to get an idea of computational AI based proof-of-concept models developed.
Weekly updates are provided with more models and results.
Welcome to AutopathX
Welcome to AutopathX
AutopathX is a translational research engine dedicated to decoding the tumor microenvironment (TME) through multi-modal spatial omics and AI-enhanced modeling. We specialize in targeted immunotherapy strategies for solid tumors, with a focus on the dynamic crosstalk between key immune players—dendritic cells, macrophages, TAMs, CAFs, and TILs.
Our mission is to bridge the gap between complex spatial biology and actionable therapeutic insights. Whether you're a biotech innovator, academic researcher, or pharma partner, AutopathX offers proof-of-concept models, immune profiling services, and biomarker discovery pipelines tailored to your translational goals.
What We Do?
What We Do?
-Spatial Omics Integration: Layer transcriptomic, proteomic, and histological data to map immune architecture
-TME Crosstalk Modeling: Simulate interactions and therapeutic responses across diverse tumor contexts
-Predictive Biomarker Discovery: Identify agnostic markers for PD1/L1 and combination therapies
-Custom Research-as-a-Service: Collaborate on bespoke projects from concept to insight
Why AutopathX?
Why AutopathX?
Precision-first approach to immunotherapy modeling
AI-enhanced analytics for immune cell detection and TME segmentation
Translational relevance for refractory and progressive disease pathways
Collaborative mindset with academic rigor and industry scalability
Why Now?
Why Now?
Agentic Multimodal AI is redefining scientific workflows — with foundation models capable of autonomously generating hypotheses, synthesizing spatial omics at single cell level resolution, and predicting immune dynamics at scale.
Compute, data, and talent have converged: GPU acceleration, LLMs, Federated Knowledge Graphs, Multi agentic RAG, open-access spatial omics immunology, oncology datasets, and a surge of cross-disciplinary expertise make high-fidelity TME modeling not only feasible but transformative.
Spatial transcriptomics (ST) technologies now resolve tumor heterogeneity at cellular resolution, illuminating immune niches and therapeutic resistance patterns.
Regulatory momentum is pushing for biomarker-informed clinical trials, creating urgency for precision modeling platforms like AutopathX.
AutopathX’s multi-modal platform integrates AI and spatial analytics to unravel crosstalk among TME players: TAMs, DCs, CAFs, macrophages, TILs using LLM foundations models, Multiagentic RAG, Federated Knowledge graphs.
Predictive POC models simulate immune interventions across diverse tumor contexts.
Our Edge
Our Edge
Academic precision with industry scalability
Early insights into refractory disease models and therapeutic resistance
AI-enhanced cross-talk modeling with spatial fidelity
Translational research partner
Page updated
Google Sites
Report abuse